Cantor Fitzgerald analyst Charles Duncan maintains $Axsome Therapeutics (AXSM.US)$ with a buy rating, and adjusts the target price from $107 to $121.
According to TipRanks data, the analyst has a success rate of 51.4% and a total average return of 24.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Axsome Therapeutics (AXSM.US)$'s main analysts recently are as follows:
Following a quarterly update that surpassed revenue expectations and provided promising pipeline developments, an analyst has acknowledged the clarification regarding the timeline of two concurrent Phase 3 Auvelity ADA trials. The simultaneous readouts expected in the fourth quarter clarify the forthcoming catalyst events. It is believed that achieving success in one of the two ADA trials may be sufficient to dispel any lingering concerns over regulatory outlooks for the crucial label expansion.
The third quarter of 2024 was notable for Axsome Therapeutics, mainly driven by a promising increase in Auvelity sales. The company remains a top selection due to the belief that it possesses the most compelling set of potential market influencers within the coverage universe through the end of the fourth quarter of 2024.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
